Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Mononuclear Cell Therapy for Limb Girdle Muscular Dystrophy
NCT02245711Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Dec 2010
- Primary completion
- Jan 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in limb-girdle muscular dystrophy (LGMD), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Functional Independence Measure at 1 year. Planned start Dec 2010; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
limb-girdle muscular dystrophy (LGMD)
Beyond the preview
Go deeper on NCT02245711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245711.